II-01 Brigitte Lacroix Modeling the anti-drug antibody response in rheumatoid arthritis patients treated with certolizumab pegol Wednesday 15:10-16:30 |
II-02 Celine M. Laffont Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients. Wednesday 15:10-16:30 |
II-03 Laure Lalande Population modelling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs Wednesday 15:10-16:30 |
II-04 Cédric Laouenan Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients Wednesday 15:10-16:30 |
II-05 Anna Largajolli The OFVPPC: A simulation objective function based diagnostic Wednesday 15:10-16:30 |
II-06 Jean Lavigne Modeling and simulation of dihydroartemisinin (DHA) after administration of Eurartesim® (piperaquine tetraphosphate/DHA) Wednesday 15:10-16:30 |
II-07 Kha Le Population PKPD Modeling of Geographic Atrophy Disease Progression, Target Mediated Disposition and Treatment Effect of Lampalizumab Wednesday 15:10-16:30 |
II-08 Jacob Leander Estimation in stochastic differential mixed-effects models Wednesday 15:10-16:30 |
II-09 Robert Leary Robust Importance Sampling for EM-based NLME Algorithms Wednesday 15:10-16:30 |
II-10 Joomi Lee Population pharmacokinetic analysis of sumatriptan in healthy Korean male subjects Wednesday 15:10-16:30 |
II-11 Giulia Lestini Two-stage adaptive designs in nonlinear mixed-effects models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic (PD) model in oncology Wednesday 15:10-16:30 |
II-12 Yan Li PK/PD Modeling of Tumor Growth Inhibition in Xenograft Mice to Optimize Experimental Design and Improve Study Efficiency Wednesday 15:10-16:30 |
II-13 Olaf Lichtenberger Evaluation of tetrahydrobiopterin responsiveness in neonates with hyperphenylalaninemia Wednesday 15:10-16:30 |
II-14 Andreas Lindauer A tool for First-in-human PK Prediction Incorporating Experimental Uncertainty Wednesday 15:10-16:30 |
II-15 Jos Lommerse PKPD model of erythropoietin and hemoglobin response in rats following administration of prolyl hydroxylase inhibitors Wednesday 15:10-16:30 |
II-16 Gaohua Lu Developing a mechanistic physiologically based lung model and its application in modelling rifampicin pharmacokinetics in the lung Wednesday 15:10-16:30 |
II-17 Merran Macpherson PPK analysis of Rouvastatin in Children and Adolescents (ages 6 to <18 years of age) with Familial Hypercholesterolemia to Support Regulatory Approval Wednesday 15:10-16:30 |
II-18 Mats Magnusson A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy Wednesday 15:10-16:30 |
II-19 Victor Mangas-Sanjuan Semi-mechanistic cell cycle PKPD model of chemotherapy-induced neutropenia Wednesday 15:10-16:30 |
II-20 Andreas Matthios Dosing recommendation for gabapentin in chronic paediatric pain Wednesday 15:10-16:30 |
II-21 Johanna Melin Population pharmacokinetic analysis of hydrocortisone in paediatric patients with adrenal insufficiency Wednesday 15:10-16:30 |
II-22 France Mentré PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R Wednesday 15:10-16:30 |
II-23 Matilde Merino-Sanjuán Simulation of Plasmatic Taurine Levels In Well And Undernourished Rats After Enteral Diet Administration. Wednesday 15:10-16:30 |
II-24 Jay Mettetal Preclinical cardiovascular risk assessment of PPAR-gamma agonist effects based on translational PK/PD modelling Wednesday 15:10-16:30 |
II-25 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Otelixizumab in vitro concentration and TCR/CD3 engagement Wednesday 15:10-16:30 |
II-26 Raymond Miller Modelling and simulation of the activity of intrinsic Factor Xa following edoxaban treatment Wednesday 15:10-16:30 |
II-27 Iris Minichmayr Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues Wednesday 15:10-16:30 |
II-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in liver transplant patients Wednesday 15:10-16:30 |
II-29 Daniel Moj Physiologically-based Pharmacokinetic (PBPK) modeling of the time-dependent drug-drug interaction (DDI) of clarithromycin and midazolam Wednesday 15:10-16:30 |
II-30 Hussain Mulla Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Wednesday 15:10-16:30 |
II-31 Helen Musther Are PBPK models reporting the right Cmax? Central venous versus peripheral site Wednesday 15:10-16:30 |
II-32 Flora Musuamba-Tshinanu Optimisation of tacrolimus-based immunosuppressive treatment in pediatric solid organ transplantation: A model-based approach. Wednesday 15:10-16:30 |
II-33 Tafireyi Nemaura In silico estimation of oral bioavailability: Implications to estimation of efavirenz PK parameters. Wednesday 15:10-16:30 |
II-34 Ida Neldemo Predicting the absolute neutrophil count with frequent measurements during docetaxel-induced myelosuppression Wednesday 15:10-16:30 |
II-35 Yookhwan Noh Population pharmacokinetics of HM781-36 and its metabolites in patients with advanced solid tumors Wednesday 15:10-16:30 |
II-36 Rikard Nordgren Automatic binning for visual predictive checks Wednesday 15:10-16:30 |
II-37 Joakim Nyberg Simulating large time-to-event trials in NONMEM Wednesday 15:10-16:30 |
II-38 Kayode Ogungbenro A physiologically based pharmacokinetic model for 6-mercaptopurine in adults and children Wednesday 15:10-16:30 |
II-39 Sean Oosterholt Covariate model selection in an Alzheimer disease progression model Wednesday 15:10-16:30 |
II-40 Ingrid Ottevaere Population pharmacokinetics of ALX-0171, an inhaled Respiratory Syncytial Virus (RSV) neutralizing Nanobody. Wednesday 15:10-16:30 |
II-41 Aziz Ouerdani Tumor growth and angiogenesis inhibition modeling: Effects of pazopanib on preclinical and clinical tumor size data Wednesday 15:10-16:30 |
II-42 Katie Owens Population K-PD modelling of lymph node size in lymphoma patients treated with abexinostat, a histone deacetylase inhibitor (HDACi). Wednesday 15:10-16:30 |
II-43 Eirini Panoilia A population PK model for bevacizumab when combined with chemotherapy in patients with metastatic colorectal cancer stage IV Wednesday 15:10-16:30 |
II-44 Sung Min Park Population pharmacokinetics and CYP3A5 genotype effect of S-amlodipine in healthy Korean male subjects Wednesday 15:10-16:30 |
II-45 Zinnia Parra-Guillen Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer Wednesday 15:10-16:30 |
II-46 Sophie Peigné Paediatric PK predictions and population analysis Wednesday 15:10-16:30 |
II-47 Nathalie Perdaems Translational PKPD modeling of a cardiovascular drug and the interrelationship between blood pressure and heart rate in animals and human Wednesday 15:10-16:30 |
II-48 Jonás Samuel Pérez-Blanco Population pharmacokinetic of doxorubicin and doxorubicinol in hematological patients Wednesday 15:10-16:30 |
II-49 Philippe Pierrillas Preclinical evaluation of the dose-concentration-marker-tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling Wednesday 15:10-16:30 |
II-50 Elodie Plan Item Response Theory Model as Support for Decision-Making: Simulation Example for Inclusion Criteria in Alzheimer's Trial Wednesday 15:10-16:30 |
II-51 Yulan Qi A Prospective Population Pharmacokinetic (PK) Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria (PKU) Wednesday 15:10-16:30 |
II-52 Gauri Rao Characterization of Oseltamivir Carboxylate (OC) Disposition using a Reduced Population (POP) Pharmacokinetic (PK) Model Wednesday 15:10-16:30 |
II-53 Yan Ren Effect of Fluticasone Furoate Treatment on Cortisol Circadian Rhythm in Healthy Chinese Subjects Wednesday 15:10-16:30 |
II-54 Renhua Zheng Population Compartmental approaches in bioequivalence studies Wednesday 15:10-16:30 |
II-55 Benjamin Ribba On the use of model-based tumor size metrics to predict survival Wednesday 15:10-16:30 |
II-56 Clémence Rigaux Modeling HbA1c dynamics in type II diabetes mellitus in patients treated with GLP-1 receptor agonist lixisenatide Wednesday 15:10-16:30 |
II-57 Rikke Meldgaard Røge Modelling of Glucose and Insulin profiles in Patients with Type 2 Diabetes Mellitus treated with a GLP-1 analogue Wednesday 15:10-16:30 |
II-58 Hyerang Roh Characterization of Nocturia Patient's Urination Pattern and Assessment of Drug Treatment Using Joint Ordered Categorical Model Wednesday 15:10-16:30 |
II-59 Trine Høyer Rose Dose-concentration-response modelling of inhibin B in controlled ovarian stimulation with FE 999049, a recombinant FSH derived from a human cell-line Wednesday 15:10-16:30 |
II-60 Adedeji Majekodunmi Mixed Effect Modelling in HCV-HIV co-infected Children Wednesday 15:10-16:30 |